Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Ansell SM, et al. Among authors: lust ja. Mayo Clin Proc. 2010 Sep;85(9):824-33. doi: 10.4065/mcp.2010.0304. Epub 2010 Aug 11. Mayo Clin Proc. 2010. PMID: 20702770 Free PMC article. Review.
Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression.
Schop RF, Jalal SM, Van Wier SA, Ahmann GJ, Bailey RJ, Kyle RA, Greipp PR, Rajkumar SV, Gertz MA, Lust JA, Lacy MQ, Dispenzieri A, Witzig TE, Fonseca R. Schop RF, et al. Among authors: lust ja. Cancer Genet Cytogenet. 2002 Jan 1;132(1):55-60. doi: 10.1016/s0165-4608(01)00526-x. Cancer Genet Cytogenet. 2002. PMID: 11801310
Review of 1027 patients with newly diagnosed multiple myeloma.
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Kyle RA, et al. Among authors: lust ja. Mayo Clin Proc. 2003 Jan;78(1):21-33. doi: 10.4065/78.1.21. Mayo Clin Proc. 2003. PMID: 12528874
Clinical course of patients with relapsed multiple myeloma.
Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Kumar SK, et al. Among authors: lust ja. Mayo Clin Proc. 2004 Jul;79(7):867-74. doi: 10.4065/79.7.867. Mayo Clin Proc. 2004. PMID: 15244382
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Lacy MQ, et al. Among authors: lust ja. Mayo Clin Proc. 2006 Aug;81(8):1047-53. doi: 10.4065/81.8.1047. Mayo Clin Proc. 2006. PMID: 16901028 Review.
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Dispenzieri A, et al. Among authors: lust ja. Mayo Clin Proc. 2007 Mar;82(3):323-41. doi: 10.4065/82.3.323. Mayo Clin Proc. 2007. PMID: 17352369
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Lacy MQ, et al. Among authors: lust ja. Mayo Clin Proc. 2007 Oct;82(10):1179-84. doi: 10.4065/82.10.1179. Mayo Clin Proc. 2007. PMID: 17908524
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. Lust JA, et al. Mayo Clin Proc. 2009 Feb;84(2):114-22. doi: 10.4065/84.2.114. Mayo Clin Proc. 2009. PMID: 19181644 Free PMC article. Clinical Trial.
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Kumar SK, et al. Among authors: lust ja. Mayo Clin Proc. 2009 Dec;84(12):1095-110. doi: 10.4065/mcp.2009.0603. Mayo Clin Proc. 2009. PMID: 19955246 Free PMC article.
282 results